SCHEMBL3668979

SCHEMBL3668979

CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cnn(CCN4CCOCC4)c3)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 11/20 0.54
GSK3B P49841 11/20 0.54
PIM1 P11309 2/20 0.51
AURKB Q96GD4 2/20 0.51
CDC7 O00311 2/20 0.51
IKBKB O14920 1/20 0.51
MAPK13 O15264 1/20 0.51
DAPK3 O43293 1/20 0.51
DYRK3 O43781 1/20 0.51
ROCK2 O75116 1/20 0.51
PRKD3 O94806 1/20 0.51
CDK1 P06493 1/20 0.51
PRKACA P17612 1/20 0.51
CDK2 P24941 1/20 0.51
MAPK1 P28482 1/20 0.51
MAPK9 P45984 1/20 0.51
CSNK1D P48730 1/20 0.51
CDK8 P49336 1/20 0.51
CLK2 P49760 1/20 0.51
MAPK12 P53778 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3669095 0.86 CDC7 (0.68) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL3665794 0.85 GSK3B (0.58) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL4294719 0.82 GSK3B (0.50) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL4284884 0.81 CDC7 (0.75) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL3668981 0.79 DYRK1A (0.52) DYRK1AGSK3BPIM1WNT1PIM3
SCHEMBL4291657 0.78 CDC7 (0.69) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL3670129 0.75 GSK3B (0.56) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL3675188 0.74 GSK3B (0.58) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL3671888 0.73 CDC7 (0.76) DYRK1AGSK3BPIM1AURKBCDC7
SCHEMBL3804773 0.73 GSK3B (0.55) DYRK1AGSK3BPIM1AURKBCDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 DYRK1A 276/4885GSK3B 1/4885PIM1 11/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 DYRK1A 276/4885GSK3B 1/4885PIM1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.